These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 18066010)

  • 1. Proposed changes to patent code loom over biotech industry.
    Coombs A
    Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
    [No Abstract]   [Full Text] [Related]  

  • 2. India's IP snub.
    Jayaraman KS
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392000
    [No Abstract]   [Full Text] [Related]  

  • 3. US courts narrow patent exemptions.
    Fox JL
    Nat Biotechnol; 2003 Aug; 21(8):834. PubMed ID: 12894182
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabilly patent finale.
    Waltz E
    Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
    [No Abstract]   [Full Text] [Related]  

  • 5. Swiss patent proposal prompts criticism.
    Burgermeister J
    Nat Biotechnol; 2004 Oct; 22(10):1323. PubMed ID: 15521096
    [No Abstract]   [Full Text] [Related]  

  • 6. The coming US patent opposition.
    Apple T
    Nat Biotechnol; 2005 Feb; 23(2):245-7. PubMed ID: 15696151
    [No Abstract]   [Full Text] [Related]  

  • 7. A nail in the coffin for DNA sequence patents?
    Yamanaka M
    Nat Biotechnol; 2008 Oct; 26(10):1085-6. PubMed ID: 18846072
    [No Abstract]   [Full Text] [Related]  

  • 8. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
    Garber K
    Science; 2006 May; 312(5775):827. PubMed ID: 16690824
    [No Abstract]   [Full Text] [Related]  

  • 9. Four rebuffs for Cabilly.
    Waltz E
    Nat Biotechnol; 2008 Apr; 26(4):362. PubMed ID: 18392001
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech as Bush bows out.
    Lorenzo A
    Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006
    [No Abstract]   [Full Text] [Related]  

  • 12. Inter partes reexamination: a potentially useful approach to challenging invalid biotechnology patents.
    Derzko NM; Behringer JW
    Nat Biotechnol; 2003 Jul; 21(7):823-5. PubMed ID: 12833101
    [No Abstract]   [Full Text] [Related]  

  • 13. Negotiating the RNAi patent thicket.
    Schmidt C
    Nat Biotechnol; 2007 Mar; 25(3):273-5. PubMed ID: 17344871
    [No Abstract]   [Full Text] [Related]  

  • 14. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 16. Unsettled expectations: how recent patent decisions affect biotech.
    Simon BM; Scott CT
    Nat Biotechnol; 2011 Mar; 29(3):229-30. PubMed ID: 21390025
    [No Abstract]   [Full Text] [Related]  

  • 17. Roche faces charges over Taq patent claim.
    Abbott A
    Nature; 1996 Aug; 382(6593):660. PubMed ID: 8751427
    [No Abstract]   [Full Text] [Related]  

  • 18. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

  • 19. Protecting rights to early-stage technology.
    Shuster MJ; Su H; Blaug S
    Nat Biotechnol; 2003 Jun; 21(6):701-3. PubMed ID: 12776151
    [No Abstract]   [Full Text] [Related]  

  • 20. Enforcing pharmaceutical and biotech patent rights in China.
    Zhang YP; Deng MM
    Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 41.